Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Read More…
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+49-211-618100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.41 billion
Profitability
Miscellaneous
Employees9,867
Next Earnings Date10/10/2019 (Estimated)
OptionableNot Optionable
Gerresheimer (ETR:GXI) Frequently Asked Questions
What is Gerresheimer's stock symbol?
Gerresheimer trades on the ETR under the ticker symbol "GXI."
When is Gerresheimer's next earnings date?
What price target have analysts set for GXI?
12 brokers have issued 1 year target prices for Gerresheimer's shares. Their predictions range from €50.00 to €87.00. On average, they expect Gerresheimer's stock price to reach €71.67 in the next year. This suggests a possible upside of 5.2% from the stock's current price. View Analyst Price Targets for Gerresheimer.
What is the consensus analysts' recommendation for Gerresheimer?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gerresheimer in the last year. There are currently 3 sell ratings, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Gerresheimer.
Has Gerresheimer been receiving favorable news coverage?
News stories about GXI stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Gerresheimer earned a news impact score of 0.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Gerresheimer.
Who are some of Gerresheimer's key competitors?
Some companies that are related to Gerresheimer include Ansell (ANN), Enerplus (ERF), Nanosonics (NAN), Advanced Medical Solutions Group (AMS), Clover (CLV), CRH Medical (CRH), Bovie Medical (BVX), Bovie Medical (BVX), CRH Medical (CRHM), CRH Medical (CRHM), TransEnterix (TRXC), Tristel (TSTL), InfuSystem (INFU), SDI (SDI) and Impression Healthcare (IHL).
What other stocks do shareholders of Gerresheimer own?
Who are Gerresheimer's key executives?
Gerresheimer's management team includes the folowing people:
- Mr. Dietmar Siemssen, CEO & Member of Management Board (Age 56)
- Dr. Lukas Burkhardt, Member of Management Board (Age 40)
- Ms. Katja Schnitzler, Group Director of Bus. Excellence & Continuous Improvement and Member of the Supervisory Board (Age 38)
- Ms. Severine Camp, Corp. Sr. Director of Investor Relations
- Mr. Jens Kürten, Group Sr. Director of Communication & Marketing and Press Officer of Corp. Media
What is Gerresheimer's stock price today?
One share of GXI stock can currently be purchased for approximately €68.15.
How big of a company is Gerresheimer?
What is Gerresheimer's official website?
How can I contact Gerresheimer?
Gerresheimer's mailing address is Klaus-Bungert-Strasse 4, DUESSELDORF, 40468, Germany. The company can be reached via phone at +49-211-618100.
MarketBeat Community Rating for Gerresheimer (ETR GXI)
MarketBeat's community ratings are surveys of what our community members think about Gerresheimer and other stocks. Vote "Outperform" if you believe GXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
